affsans résumé
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)2008· article· en· The Lancet· Immunology and Microbiology
1 865
citations